keyword
MENU ▼
Read by QxMD icon Read
search

ADT

keyword
https://www.readbyqxmd.com/read/29137489/androgen-deprivation-therapy-for-the-treatment-of-prostate-cancer-a-focus-on-pharmacokinetics
#1
Charles F Polotti, Christopher J Kim, Nadiya Chuchvara, Alyssa B Polotti, Eric A Singer, Sammy Elsamra
Medical therapy has undergone many changes as our understanding of prostate cancer cell biology has improved. Androgen deprivation therapy (ADT) remains the mainstay of therapy for metastatic disease. Metastatic castrate-resistant prostate cancer (CRPC) is an important concern since we are unable to stop progression with currently available agents. Areas covered: Pharmacologic ADT is the most commonly used treatment for metastatic prostate cancer. Multiple agents are available for both first-line and second-line use: antiandrogens, estrogens, luteinizing hormone-releasing hormone agonists/antagonists, and CYP17 inhibitors...
November 15, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29134684/enhanced-radiosensitization-of-enzalutamide-via-schedule-dependent-administration-to-androgen-sensitive-prostate-cancer-cells
#2
Maryam Ghashghaei, Miltiadis Paliouras, Mitra Heravi, Hamed Bekerat, Mark Trifiro, Tamim M Niazi, Thierry Muanza
BACKGROUND: Prostate cancer (PCa) is a progressive disease and the most diagnosed cancer in men. The current standard of care for high-risk localized PCa is a combination of androgen deprivation therapy (ADT) and radiation (XRT). The majority of these patients however become resistant due to incomplete responses to ADT as a result of selective cells maintaining androgen receptor (AR) activity. Improvement can be made if increasing radiosensitivity is realized. Therefore, the aim of this study is to investigate the efficacy of the next-generation PCa drug Enzalutamide (ENZA), as a radiosensitizer in XRT therapy...
November 14, 2017: Prostate
https://www.readbyqxmd.com/read/29132550/cytoreductive-cryosurgery-in-patients-with-bone-metastatic-prostate-cancer-a-retrospective-analysis
#3
Ming-Xiong Sheng, Ling-Ling Wan, Chang-Ming Liu, Chun-Xiao Liu, Shu-Shang Chen
The current study is a retrospective analysis of 49 patients with bone metastatic prostate cancer: 26 receiving androgen deprivation therapy (ADT) alone versus 23 receiving cytoreductive cryosurgery of the primary tumor plus ADT treatment. Progression-free survival (PFS) was the primary outcome variable, and Cox proportional hazards regression analysis was used to identify predictors for PFS. The baseline characteristics were generally comparable between the 2 groups. Median follow-up time was 41 months (range 24-56) and 37 months (range 19-53) in ADT alone group and cryosurgery groups, respectively...
December 2017: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/29128208/multi-institutional-evaluation-of-elective-nodal-irradiation-and-or-androgen-deprivation-therapy-with-postprostatectomy-salvage-radiotherapy-for-prostate-cancer
#4
Stephen J Ramey, Shree Agrawal, Matthew C Abramowitz, Drew Moghanaki, Thomas M Pisansky, Jason A Efstathiou, Jeff M Michalski, Daniel E Spratt, Jason W D Hearn, Bridget F Koontz, Stanley L Liauw, Alan Pollack, Mitchell S Anscher, Robert B Den, Kevin L Stephans, Anthony L Zietman, W Robert Lee, Andrew J Stephenson, Rahul D Tendulkar
BACKGROUND: Outcomes with postprostatectomy salvage radiation therapy (SRT) are not ideal. Little evidence exists regarding potential benefits of adding whole pelvic radiation therapy (WPRT) alone or in combination with androgen deprivation therapy (ADT). OBJECTIVE: To explore whether WPRT and/or ADT added to prostate bed radiation therapy (PBRT) improves freedom from biochemical failure (FFBF) or distant metastases (DM). DESIGN, SETTING, AND PARTICIPANTS: A database was compiled from 10 academic institutions of patients with postprostatectomy prostate-specific antigen (PSA) >0...
November 8, 2017: European Urology
https://www.readbyqxmd.com/read/29124881/the-implications-of-baseline-bone-health-assessment-at-initiation-of-androgen-deprivation-therapy-for-prostate-cancer
#5
Peter S Kirk, Tudor Borza, Vahakn B Shahinian, Megan E V Caram, Danil V Makarov, Jeremy B Shelton, John T Leppert, Ryan M Blake, Jennifer A Davis, Brent K Hollenbeck, Anne Sales, Ted A Skolarus
OBJECTIVES: To assess bone density testing (BDT) use among prostate cancer survivors receiving ADT, and downstream implications for osteoporosis and fracture diagnoses as well as pharmacologic osteoporosis treatment in a national integrated delivery system. METHODS: We identified 17,017 men with prostate cancer who received any ADT between 2005 and 2014 using Veterans Health Administration cancer registry and administrative data. We identified claims for BDT within a 3-year period of ADT initiation...
November 10, 2017: BJU International
https://www.readbyqxmd.com/read/29123014/positron-emission-tomography-using-a-grpr-antagonist-68-ga-rm26-in-healthy-volunteers-and-prostate-cancer-patients
#6
Jingjing Zhang, Gang Niu, Xingrong Fan, Lixin Lang, Guozhu Hou, Libo Chen, Huanwen Wu, Zhaohui Zhu, Fang Li, Xiaoyuan Chen
This study was designed to study the safety, biodistribution, radiation dosimetry of a gastrin-releasing peptide receptor (GRPR) antagonist positron emission tomography (PET) tracer (68)Ga-RM26, to assess its clinical diagnostic value in prostate cancer patients, and to perform a direct comparison between GRPR antagonist (68)Ga-RM26 and agonist (68)Ga-BBN. Methods: Five healthy volunteers were enrolled to validate the safety of (68)Ga-RM26 and calculate dosimetry. A total of 28 patients with prostate cancer (17 newly diagnosed and 11 post therapy) were recruited with written informed consent...
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29116258/prostate-cancer-treatment-after-adt-plus-docetaxel
#7
Clemens Thoma
No abstract text is available yet for this article.
November 8, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29113772/oncologic-outcomes-of-definitive-treatments-for-low-and-intermediate-risk-prostate-cancer-after-a-period-of-active-surveillance
#8
Michael J Whalen, Jamie S Pak, Danny Lascano, David Ahlborn, Justin T Matulay, James M McKiernan, Mitchell C Benson, Sven Wenske
BACKGROUND: To compare oncologic outcomes of different definitive treatment (DT) modalities in a cohort of patients with prostate cancer (PCa) after active surveillance (AS). METHODS: We identified 237 patients with National Comprehensive Cancer Network (NCCN) low- and intermediate-risk prostate cancer diagnosed from 1990 to 2012 who did not undergo immediate DT within 12 months of diagnosis (ie, AS patients as well as watchful waiting and those refusing DT). Charts were examined for clinical/pathologic data and type of DT: surgery (RP), radiation including brachytherapy (XRT), cryotherapy, and androgen deprivation therapy monotherapy (ADT)...
October 16, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29107277/newly-diagnosed-metastatic-prostate-cancer-has-the-paradigm-changed
#9
REVIEW
Shivashankar Damodaran, Christos E Kyriakopoulos, David F Jarrard
Androgen deprivation therapy (ADT) has been conventional treatment of newly diagnosed metastatic prostate cancer for more than 70 years. However, all patients eventually become castration-resistant and a significant proportion of life span is spent in the castration-resistant state. Prospective randomized control trials have incorporated early chemotherapy along with ADT based on the hypothesis that a significant level of resistance to ADT already exists in newly diagnosed metastatic prostate cancer and ADT exhibits synergistic antitumor activity with taxanes...
November 2017: Urologic Clinics of North America
https://www.readbyqxmd.com/read/29105980/extracellular-vesicles-in-the-adaptive-process-of-prostate-cancer-during-inhibition-of-androgen-receptor-signalling-by-enzalutamide
#10
Carolina Soekmadji, Anja Rockstroh, Grant A Ramm, Colleen C Nelson, Pamela J Russell
Current treatments for advanced prostate cancer focus on inhibition of the androgen receptor (AR) by androgen deprivation therapy (ADT). However, complex interactions mediated by tumour suppressors, oncogenes, aberrations of AR expression, or de novo androgen production have been shown to induce the adaptive response of prostate cancer, leading to the development of castration resistant prostate cancer (CRPC). In this study, we report the effects of AR antagonist, enzalutamide on the protein contents of extracellular vesicles (EVs)...
November 6, 2017: Proteomics
https://www.readbyqxmd.com/read/29103760/updated-guidelines-for-metastatic-hormone-sensitive-prostate-cancer-abiraterone-acetate-combined-with-castration-is-another-standard
#11
EDITORIAL
Nicolas Mottet, Maria De Santis, Erik Briers, Silke Gillessen, Jeremy P Grummet, Thomas B Lam, Henk G van der Poel, Olivier Rouvière, Roderick C Van den Bergh, Philip Cornford
Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard of care for newly diagnosed mHSPC.
November 2, 2017: European Urology
https://www.readbyqxmd.com/read/29102054/cognitive-function-in-patients-on-androgen-suppression-a-prospective-multicentric-study
#12
J Morote, Á J Tabernero, J L Álvarez-Ossorio, J P Ciria, J L Domínguez-Escrig, F Vázquez, J Angulo, F J López, R de La Iglesia, J Romero
OBJECTIVE: To assess the effect of androgen deprivation therapy (ADT) on cognitive performance (CP) in patients with prostate cancer (PCa) after 6 months of treatment with luteinizing hormone-releasing hormone (LHRH) analogues. MATERIAL AND METHODS: Prospective, observational, multicentre, open-label study of patients diagnosed with nonmetastatic or asymptomatic metastatic PCa scheduled to receive LHRH analogues for≥6 months. We assessed four CP domains at baseline and after 6 months of ADT: 1) Working memory: Wechsler Adult Intelligence Scale III (WAIS III) Digit Span Subtest (WAIS III-Digit); 2) Visual memory: ad hoc visual memory test; 3) Visuospatial ability: Judgement of Line Orientation (JLO) and Mental Rotation of Three-Dimensional Objects (3D-Rotation); and 4) Nonverbal analytical reasoning: WAIS III Matrix Reasoning Test (WAIS III-MRT)...
October 25, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/29091915/affect-during-incremental-exercise-the-role-of-inhibitory-cognition-autonomic-cardiac-function-and-cerebral-oxygenation
#13
Weslley Quirino Alves da Silva, Eduardo Bodnariuc Fontes, Rodrigo Menezes Forti, Zayonara Larissa Lima, Daniel Gomes da Silva Machado, Andréa Camaz Deslandes, Erika Hussey, Nathan Ward, Rickson Coelho Mesquita, Alexandre Hideki Okano, Hassan Mohamed Elsangedy
BACKGROUND: Pleasure is a key factor for physical activity behavior in sedentary individuals. Inhibitory cognitive control may play an important role in pleasure perception while exercising, especially at high intensities. In addition, separate work suggests that autonomic regulation and cerebral hemodynamics influence the affective and cognitive responses during exercise. PURPOSE: We investigated the effects of exercise intensity on affect, inhibitory control, cardiac autonomic function, and prefrontal cortex (PFC) oxygenation...
2017: PloS One
https://www.readbyqxmd.com/read/29091406/application-of-x-ray-diffraction-and-electron-crystallography-for-solving-complex-structure-problems
#14
Jian Li, Junliang Sun
All crystalline materials in nature, whether inorganic, organic, or biological, macroscopic or microscopic, have their own chemical and physical properties, which strongly depend on their atomic structures. Therefore, structure determination is extremely important in chemistry, physics, materials science, etc. In the past centuries, many techniques have been developed for structure determination. The most widely used one is X-ray crystallography (single-crystal X-ray diffraction (SCXRD) and powder X-ray diffraction (PXRD)), and it remains the most important technique for structure determination of crystalline materials...
November 1, 2017: Accounts of Chemical Research
https://www.readbyqxmd.com/read/29080287/contemporary-salvage-post-prostatectomy-radiotherapy-early-implementation-improves-biochemical-control
#15
Andrew Kneebone, George Hruby, Georgia Harris, Kris Rasiah, Justin Vass, Deborah Whalley, Philip McCloud, Sandra Louw, Linxin Guo, Thomas Eade
INTRODUCTION: The optimal time to commence salvage radiotherapy (SRT) for a rising PSA post radical prostatectomy is not known. We wished to assess the impact of index PSA (iPSA) level prior to SRT on rates of biochemical failure (BCF) post treatment. METHODS: Patients referred to our institution for SRT for a rising PSA post surgery were accrued onto a prospective database. Baseline demographic data, tumour and treatment factors were collected including pathologic T and N stage, margin status, Gleason score (GS), lymphovascular space invasion (LVSI), use of androgen deprivation therapy (ADT) and time from surgery to salvage radiotherapy...
October 28, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/29074079/high-dose-rate-brachytherapy-as-monotherapy-for-localised-prostate-cancer
#16
Iosif Strouthos, Nikolaos Tselis, Georgios Chatzikonstantinou, Saeed Butt, Dimos Baltas, Dimitra Bon, Natasa Milickovic, Nikolaos Zamboglou
BACKGROUND AND PURPOSE: To evaluate the oncological outcome of a three-implant high dose rate (HDR) brachytherapy (BRT) protocol as monotherapy for clinically localised prostate cancer. MATERIAL AND METHODS: Between February 2008 and December 2012, 450 consecutive patients with clinically localised prostate cancer were treated with HDR monotherapy. The cohort comprised of 198 low-, 135 intermediate- and 117 high risk patients being treated with three single-fraction implants of 11...
October 23, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29074061/anticancer-activity-and-tolerance-of-treatments-received-beyond-progression-in-men-treated-upfront-with-androgen-deprivation-therapy-with-or-without-docetaxel-for-metastatic-castration-na%C3%A3-ve-prostate-cancer-in-the-getug-afu-15-phase-3-trial
#17
Pernelle Lavaud, Gwenaëlle Gravis, Stéphanie Foulon, Florence Joly, Stéphane Oudard, Frank Priou, Igor Latorzeff, Loïc Mourey, Michel Soulié, Remy Delva, Ivan Krakowski, Brigitte Laguerre, Christine Théodore, Jean Marc Ferrero, Philippe Beuzeboc, Muriel Habibian, Frédéric Rolland, Gael Deplanque, Damien Pouessel, Sylvie Zanetta, Jean François Berdah, Jerome Dauba, Marjorie Baciuchka, Christian Platini, Claude Linassier, Nicole Tubiana-Mathieu, Jean Pascal Machiels, Claude El Kouri, Alain Ravaud, Etienne Suc, Jean Christophe Eymard, Ali Hasbini, Guilhem Bousquet, Stéphane Culine, Jean-Marie Boher, Gabrielle Tergemina-Clain, Clémence Legoupil, Karim Fizazi
BACKGROUND: Androgen deprivation therapy (ADT) plus docetaxel is the standard of care in fit men with metastatic castration-naive prostate cancer (mCNPC) following results from GETUG-AFU 15, CHAARTED, and STAMPEDE. No data are available on the efficacy of treatments used for metastatic castration-resistant prostate cancer (mCRPC) in men treated upfront with ADT plus docetaxel for mCNPC. OBJECTIVE: To investigate the efficacy and tolerance of subsequent treatments in patients treated upfront with chemo-hormonal therapy for mCNPC...
October 23, 2017: European Urology
https://www.readbyqxmd.com/read/29072790/sleep-disturbance-in-men-receiving-androgen-deprivation-therapy-for-prostate-cancer-the-role-of-hot-flashes-and-nocturia
#18
Brian D Gonzalez, Brent J Small, Mallory G Cases, Noelle L Williams, Mayer N Fishman, Paul B Jacobsen, Heather S L Jim
BACKGROUND: Patients with prostate cancer receiving androgen deprivation therapy (ADT) are at risk of sleep disturbance; however, to the authors' knowledge, the mechanisms by which ADT may affect sleep are not well understood. The current study compared objective and subjective sleep disturbance in ADT recipients and controls and examined whether sleep disturbance in ADT recipients is attributable to the influence of ADT on hot flashes and nocturia. METHODS: Patients with prostate cancer were assessed before or within 1 month after the initiation of ADT as well as 6 months and 12 months later (78 patients)...
October 26, 2017: Cancer
https://www.readbyqxmd.com/read/29069851/discrepancies-on-the-association-between-androgen-deprivation-therapy-for-prostate-cancer-and-subsequent-dementia-meta-analysis-and-meta-regression
#19
Jae Heon Kim, Bora Lee, Deok Hyun Han, Kyoung Jin Chung, In Gab Jeong, Benjamin I Chung
Limited literature exists on the association between androgen deprivation therapy (ADT) for prostate cancer (PCa) and subsequent dementia and the study conclusions are in conflicts with one another. We searched several cohort databases from 1960 to 2017 for observational or prospective studies that reported on an association between ADT for PCa and subsequent dementia. A meta-analysis was performed to cumulatively determine the association between ADT and dementia including Alzheimer's disease using an incidence rate ratio (IRR), crude hazard ratio (HR), and adjusted HR...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29067142/intermittent-96-hour-auricular-electroacupuncture-for-hot-flashes-in-patients-with-prostate-cancer-a-pilot-study
#20
Tyvin Rich, Gerald W Porter, Luisel Ricks-Santi, Tzvi Milshtein, Thomas Corbin
Objective: The hot flash is a common vasomotor disorder that causes distress in menopausal women and that can be debilitating in men with prostate cancer who are treated with androgen deprivation therapy (ADT). The utility of auricular electroacupuncture (AEA) was tested exclusively for a small cohort of men with ADT-induced vasomotor symptoms while the men underwent a course of curative radiotherapy. Materials and Methods: Prior to and during radiotherapy treatment, men with vasomotor symptoms were given repeated questionnaires regarding severity and frequency of hot flashes, quality of life (QoL), and sleep over a 6-week span of an AEA protocol...
October 1, 2017: Medical Acupuncture
keyword
keyword
58121
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"